Alzheimer disease
A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.
Read more about Alzheimer diseaseTrial-stage treatments and research studies you can joinOpen trials for referral
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Filters
- Tests KarXT with KarX-EC for memory and thinking problems in Alzheimer's disease
Tests KarXT with KarX-EC against a placebo in people with mild to moderate Alzheimer's.
Amsterdam, NetherlandsAlso 's-Hertogenbosch, ZwolleAge 60 to 85 - Testing KarXT with KarX-EC for memory problems in Alzheimer's disease
Tests KarXT with KarX-EC against placebo in adults with mild to moderate Alzheimer's disease.
Amsterdam, NetherlandsAlso 's-Hertogenbosch, ZwolleAge 60 to 85 - Tests ALN-APP, an injected drug, in early-onset Alzheimer's disease
Tests the safety of ALN-APP, given by spinal injection, in adults with early-onset Alzheimer's.
Amsterdam, NetherlandsAge 18+ - Testing MK-2214 in people with early Alzheimer's disease
Tests whether MK-2214 slows tau buildup in adults with early Alzheimer's disease.
Amsterdam, NetherlandsAlso 's-Hertogenbosch, ZwolleAge 50 to 85 - Mivelsiran Tested in Early Down Syndrome-Associated Alzheimer's Disease
Tests mivelsiran against placebo in adults with early Down syndrome-associated Alzheimer's disease.
Amsterdam, NetherlandsAge 40 to 55 - Tests ALN-5288 injected into the spinal fluid for Alzheimer's disease
Tests ALN-5288, given into the spinal fluid, in adults with Alzheimer's disease.
Amsterdam, NetherlandsAlso 's-HertogenboschAge 40 to 80 - Tests remternetug in people with an Alzheimer's-causing gene mutation
Tests remternetug against placebo in adults with a gene mutation causing early Alzheimer's.
Amsterdam, NetherlandsAge 18+ - Tests remternetug in people at risk for early-onset familial Alzheimer disease
Tests remternetug against placebo in adults with a genetic mutation causing Alzheimer disease.
Amsterdam, NetherlandsAge 18+ - Testing DNL628 for Safety in People With Early Alzheimer's Disease
Tests DNL628 against a placebo in adults with early Alzheimer's disease.
Amsterdam, NetherlandsAlso 's-Hertogenbosch, ZwolleAge 18 to 75 - Tests magnetic brain stimulation to slow thinking decline in Alzheimer's disease
Tests repetitive magnetic stimulation of the precuneus in adults with early-onset Alzheimer's disease.
Amsterdam, NetherlandsAge 50 to 85 - Amsterdam, NetherlandsAge 18+
- Testing Treatments to Slow Early Alzheimer's in People with Inherited Gene Changes
Tests investigational drugs against placebo in adults with inherited Alzheimer's gene mutations.
NetherlandsAge 18+ - Long-Term Registry Following People With Alzheimer's and Related Dementias
Collects routine clinical information from adults with Alzheimer's disease over many years.
Amsterdam, NetherlandsAge 18+ - Studies biomarkers that may predict Alzheimer's in people with inherited mutations
Looks for signs that may predict Alzheimer's disease in adults carrying a gene mutation.
Amsterdam, NetherlandsAge 18+ - Tests a new PET scan tracer for TDP-43 protein in the brain
Tests a brain imaging tracer in adults with suspected TDP-43 diseases and healthy people.
Amsterdam, NetherlandsAge 40 to 70 - Blood tests for earlier and more accurate diagnosis of Alzheimer's disease
Tests whether blood biomarker results help memory clinics diagnose Alzheimer's disease.
Almere Stad, NetherlandsAlso Amsterdam, Haarlem, Hilversum, Leeuwarden, Purmerend, 's-Hertogenbosch, TilburgAge 55+ - Tests efavirenz in adults with early Alzheimer's disease
Tests efavirenz, a drug, in adults with early Alzheimer's disease.
Amsterdam, NetherlandsAge 18+ - PET brain scan tracer measures a brain barrier protein in neurodegenerative disease
Tests a radioactive brain scan tracer in adults with Alzheimer's, amyloid angiopathy or Parkinson's.
Groningen, NetherlandsAge 18+
Search the publications
The results open on the publications page in a new tab, so this page stays as it is.
Lists with this disease filtered
Where treatment stands
In the EU, lecanemab was first approved in April 2025 and donanemab in September 2025.
Approved: 12
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 29
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 5
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Lab research stage: 1
Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.
Support organisations
Patient organisations and helplines in Netherlands, for you and your family.
Alzheimer disease organisations in Netherlands
- DementieLijn (Alzheimer Nederland)
Alzheimer Nederland's free phone line offering a listening ear and advice on living with dementia.
- Alzheimer Nederland
National Alzheimer association with a free advice line (Dementielijn). Number and hours were not readable on the pages opened today.
- Rijksoverheid – Dementie
Dutch central government dementia pages: what to know and arrange after a diagnosis, and the National Dementia Strategy.
General support in Netherlands
- 113 Zelfmoordpreventie
Dutch national suicide prevention line, reachable 24/7 by phone (113 or 0800-0113) and chat, anonymous and free.
- De Luisterlijn
Dutch volunteer listening line offering a listening ear day and night by phone (088 0767 000), chat and e-mail.
International organisations
- Alzheimer's Association
Free 24/7 Helpline (interpreters for 200+ languages), care consultations with dementia experts, local chapters, Community Resource Finder, ALZConnected online community.
- Alzheimer's Drug Discovery Foundation
Funds the early work on new Alzheimer's medicines, in universities and companies.
- BrightFocus Foundation
US nonprofit that funds research and provides public information on Alzheimer's disease, macular degeneration and glaucoma.
- Dementia Alliance International (DAI)
Organisation for people with a dementia diagnosis: free online peer support groups, webinars, Brain Health Hub, resources for care partners.
Frontlight Community
Alzheimer disease community in Netherlands
People living with Alzheimer disease and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.
You need a Frontlight account with a verified e-mail address to comment.
Offer tissue or data
There are three ways to help research move faster.
Approved treatments
12 medicines are approved for Alzheimer disease in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.
Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 4 uncertain matches are left out. Other countries' own approvals were not checked.
“Miracle cure” fact checker
Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
“Cures” others already fact-checked
See all 2About Alzheimer disease
Sources: NHS, MedlinePlus, Archives of Neurology
A brain disease that slowly harms memory and thinking, and the most common cause of dementia in older people. Medicines cannot stop it, but some can keep the symptoms from getting worse for a while. Most people who get it are over 65, and the risk rises with age: about 1 in 6 people over 80 has it or another type of dementia. The changes in the brain start many years before the first signs appear.
What is it?
Alzheimer's is the most common cause of dementia: a steady loss of memory, thinking and other mental abilities. Proteins build up in and around brain cells. One protein (amyloid) forms clumps around the cells, another (tau) forms tangles inside them. Over time parts of the brain shrink, usually the memory areas first. These changes begin many years before any signs. It is not a normal part of getting older.
Most people who get it are over 65, and the risk rises with age: about 1 in 14 people over 65 and 1 in 6 over 80 have Alzheimer's or another type of dementia. Genes usually raise the risk only a little. In a few families a single gene causes it, and then it is much more likely to be passed on.
The first signs
The signs come on slowly over several years and are sometimes taken for normal ageing.
- forget recent conversations or events;
- misplace things and forget the names of places and objects;
- struggle to find the right word, or ask the same questions again and again;
- find decisions harder and become more hesitant about trying new things;
- feel anxious, agitated or confused at times.
How doctors find out
There is no simple, reliable test. The doctor checks your general health, may order blood tests and ask about your medicines to rule out other causes, and asks you to do some memory and thinking tasks. You may then be sent to a specialist, who may work at a memory clinic, for more tests such as a brain scan (CT or MRI). Finding out can take many months and several appointments.
Current treatment
Symptom medicines (e.g. donepezil) plus support
Will it get worse?
Yes. It is a progressive illness: the symptoms get worse slowly over several years. It gets worse slowly, at a different pace for each person. In the middle stage people usually need support with everyday living, such as help with eating, washing, getting dressed and using the toilet. In the severe stages they may need full-time care. People may live for several years after the signs begin, but this varies a lot. Alzheimer's shortens life, though many people with it die of something else.
Medicines: what helps, and what to watch for
Medicines cannot cure Alzheimer's, but some can ease the symptoms for a time. Donepezil, galantamine and rivastigmine raise acetylcholine, a brain chemical that helps nerve cells pass messages; they are used in the early and middle stages. Memantine works in a different way and is used when the disease is moderate or severe.
Good to know:
- specialists, such as psychiatrists or neurologists, can prescribe these medicines; your family doctor may prescribe them on a specialist's advice;
- feeling sick, being sick and losing your appetite can be side effects, and they usually get better after about 2 weeks;
- memantine can cause headaches, dizziness and constipation, which usually pass;
- for aggression or extreme distress, other ways of coping are tried first; antipsychotic medicines have serious side effects, so they should be used at the lowest dose for the shortest time possible.
Exercise and therapy help too
Some treatments without medicines can help memory, problem solving, mood and wellbeing:
- cognitive stimulation therapy: group activities and exercises for memory and problem solving;
- cognitive rehabilitation: working with a professional, such as an occupational therapist, and a relative or friend towards a personal goal, like using a mobile phone;
- reminiscence and life story work: talking about the past with the help of photos, objects or music.
Exercise regularly, for example with a daily walk, gardening, tai chi or dancing.
Median survival
About 3 to 8 years after diagnosis, depending on age at diagnosis
Measured in: Participants of the Baltimore Longitudinal Study of Aging older than 55, followed 1985–1999
The figures behind it
Baltimore Longitudinal Study of Aging (participants older than 55, followed 1985–1999): median survival 8.3 years when Alzheimer disease was diagnosed at age 65, down to 3.4 years when it was diagnosed at age 90; no significant difference between men and women.
Sources
Written in plain words by Frontlight from these pages:
- MedlinePlus: Alzheimer's Disease
- NHS: Alzheimer's disease – Overview
- NHS: Alzheimer's disease – Causes
- NHS: Alzheimer's disease – Symptoms
- NHS: Alzheimer's disease – Diagnosis
- NHS: Alzheimer's disease – Treatment
- NHS: Living well with dementia
- Archives of Neurology: Survival following a diagnosis of Alzheimer disease